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Genome-wide association studies (GWAS) have identified tens of risk loci for many complex 1 
disorders including Crohn’s disease (CD)1,2.  However, common disease-associated SNPs explain at 2 
most 20% of genetic variance.  Several factors may account for the missing heritability3-5, 3 
including rare risk variants not adequately tagged in GWAS6-8.  That rare susceptibility variants 4 
indeed contribute to the variation of multifactorial phenotypes has been demonstrated for 5 
colorectal cancer9, plasma levels of HDL cholesterol10, blood pressure11, type I diabetes12, 6 
hypertriglyceridemia13 and - in the case of CD – for the NOD2 gene14,15.  We herein describe the use 7 
of high-throughput resequencing of DNA pools to search for rare coding variants influencing 8 
susceptibility to CD in 63 GWAS-identified positional candidate genes.  We report low frequency 9 
coding variants conferring protection against inflammatory bowel disease (IBD) in the IL23R gene, 10 
yet conclude that rare coding variants in positional candidates don’t make a large contribution to 11 
inherited predisposition to CD. 12 
A meta-analysis of three GWAS resulted in the identification of 30 significant and 10 suggestive 13 
susceptibility loci for CD2.  The average confidence interval was 233 Kb (range: 20 to 1,140) 14 
encompassing 4.1 genes (range: 0 to 37) for a total of 153 positional candidates (Supplemental Table 15 
1).  We decided to sequence the open reading frame (ORF) and intron-exon boundaries of the 51 16 
genes mapping to loci containing between one and five genes.  For loci with more than six 17 
candidates, we retained 15 genes that mapped to significant networks identified when analyzing all 18 
candidates with Ingenuity Pathways (v8.5) (Supplemental Table 2).  To these 66 genes, we added the 19 
SLC22A4 candidate16, as well as PTGER4, ORMDL3 and GSDMB on the basis of reported cis-eQTL 20 
effects2,17.  The list of 70 selected genes is provided in Supplemental Table 3.  21 
After extensive optimization (cfr. Supplemental note 1), we selected a protocol involving (i)  22 
constitution of equimolar pools of genomic DNA from sets of 32 cases or controls, (ii) amplification, 23 
using Phusion Hot Start High Fidelity DNA Polymerase (Finnzymes Oy), of the 70 targeted ORFs and 24 
intron-exon boundaries as a series of 1,045 amplicons averaging 222 bp (range: 136-337 bp) (iii)  25 
equimolar pooling of 300 amplicons, (iv) massive parallel pyrosequencing using the Roche FLX 26 
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system18 targeting an average sequence depth of 500 for both the Watson and Crick (W&C) strands, 1 
(v) detection of DNA sequence variants (DSV) using the Amplicon Variant Analyzer (AVA) software 2 
(Roche) augmented with custom-made scripts (Methods).   3 
We opted for a staged design in which all 70 candidate genes would first (stage I) be sequenced on 4 
112 cases and 112 controls. This provides 98.5% and 73.3% nominal power (p ≤ 0.05) to detect the 5 
12% and 7% excess of rare NOD2 variants reported by Hugot et al.14 and Lesage et al.15 respectively.  6 
The most promising genes would be further evaluated on additional pools of cases and controls 7 
(stage II).  To increase the impact of genetic effects other than NOD2, the 112 stage I cases did not 8 
carry either of three known NOD2 susceptibility variants (p.R702W, p.G908R and p.A1007fs).  To 9 
avoid subtle stratification, the corresponding 112 controls underwent the same selection.  All 10 
analyzed cases and controls were of European decent.  11 
92.9% of amplicons, corresponding to 63/70 genes (Supplemental Table 3) and 108.3 kb, could be 12 
sequenced with coverage ≥ 200 for both W&C strand in at least one case and one control pool.  13 
Simulations indicate that this coverage provides ≥ 83.4% power to detect singletons (i.e. one variant 14 
chromosome in DNA pool of 32 individuals) given the settings of the AVA software and self-imposed 15 
curation filters (Supplemental Fig.1).  Average sequence depth (± SD) of retained amplicons was 16 
1,471 ± 849 in cases and 1,420 ± 822 in controls (Supplemental Table 3).  Analysis of the flowgrams 17 
yielded 372 DSV (Table 1, Supplemental Table 4).  Transitions accounted for 82.5%, transversions for 18 
16.1%, dinucleotide substitutions for 0.3% and indels for 1.1% of the variants. Synonymous (S) 19 
variants accounted for 41.7%, missense variants for 55.9%, nonsense variants for 0.8%, in-frame 20 
indels for 1.1%, and “boundary” (intronic within 2 bp from exon) (β) variants for 0.5%.  DSV with 21 
estimated MAF < 0.05 amounted to 78.5%, while singletons represented 50.3% of the total (Fig. 1).  22 
As expected and reflecting purifying selection on (mildly) deleterious variants, the frequency 23 
spectrum of non-synonymous (NS) variants was shifted towards lower frequencies when compared 24 
to S variants.  NS variants represented 60% of the total for MAF < 0.05 versus 40% for MAF ≥ 0.05 25 
(Table 1 & Fig. 1).  The high transition/transversion ratio (5.1) is thought to be due to (i) the analysis 26 
Momozawa et al.  Page 4/13 
of ORF, as transversions are more likely to be NS and selected against, (ii) idiosyncrasies of the 1 
analyzed set of genes as their transition/transversion ratio tended to be higher than that of other 2 
ORF in HapMap data, and (iii) the elimination of low frequency (< 2.5%) C-A=G-T variants 3 
(Supplemental Table 5 and Supplemental note 1).     4 
We evaluated our protocol in terms of sensitivity (fraction of true variants called), positive predictive 5 
value (PPV; fraction of true variants amongst called variants), and accuracy in estimating allelic 6 
frequency, focusing first on common variants (MAF ≥ 0.05).  Analysis of the HapMap data revealed 62 7 
bona fide SNPs with MAF ≥ 0.05 that were covered by the 879 retained amplicons.   Five of these (= 8 
8.1%) would lie within 6 bp from a homopolymer track and ignored (Methods).  The remaining 57 9 
were all detected, pointing towards excellent sensitivity.  The 24 called SNPs with MAF ≥ 0.05 that 10 
were not genotyped in HapMap were inventoried in dbSNP (22/24 SNPs) or confirmed by the 1,000 11 
Genomes Project (www.1000genomes.org/) (2 remaining), indicating excellent PPV.  To evaluate the 12 
accuracy in estimating allelic frequencies we took advantage of 31 common SNPs that had been 13 
genotyped on the same individuals as part of other projects.  Supplemental Fig. 2 shows the 14 
correlation between allelic frequency estimated from the genotyping data and read counts.  The 15 
regression coefficient was 0.975 and the correlation 0.993. 16 
To obtain similar estimates for rare variants, we manually (Sanger sequencing on ABI3730) 17 
sequenced 2,283bp of the NOD2 ORF on the same 112 cases and 112 controls.  Sanger sequencing 18 
revealed 38 variants with MAF < 0.05.  Assuming faultless Sanger sequencing, sensitivity and PPV of 19 
the massive parallel resequencing protocol were 82.4% and 97.9%.  Frequency estimates from read 20 
counts tended to underestimate actual frequencies of rare variants (regression coefficient: 0.822; 21 
correlation: 0.578) (Supplemental Fig. 2).  We observed no difference in sequence depth between 22 
amplicon x DNA pool combinations in which rare DSV were detected and those in which no such DSV 23 
were found (Supplemental Fig. 3). 24 
Having evaluated the performances of our protocol, we initiated the search for differences in 25 
cumulative frequencies of rare variants (MAF < 0.05) between cases and controls.  Statistical 26 
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significance of the observed differences was estimated on a gene-by-gene basis using a permutation 1 
test (Methods).  P-values were computed for (i) S variants, (ii) all NS+β variants, and (iii) NS variants 2 
predicted by SIFT19 to be damaging. For each gene x DSV-type combination we computed two p-3 
values corresponding, respectively, to an enrichment of rare variants in cases (i.e. risk variants), or an 4 
enrichment of rare variants in controls (i.e. protective variants).  Thus, we made the hypothesis that 5 
disruptive variants would increase disease-risk in some genes, while decreasing disease-risk in others.  6 
When applying a Bonferroni correction, none of the 63 sequenced genes showed a significant (p < 7 
7.94 x 10-4) enrichment of rare variants neither in cases nor in controls, whether S, NS+β or damaging 8 
(Supplemental Table 6).  There was no evidence for a difference in the distribution of p-values 9 
between S and NS+β variants, whether considering variants independently or on a gene-by-gene 10 
basis (Supplemental note 2).  However, NOD2 was showing the expected enrichment of rare NS 11 
variants (excluding the well known p.R702W, p.G908R, and p.A1007fs DSV) in cases (nominal p = 5.94 12 
x 10-3; rank 3).   13 
We therefore decided to pursue the sequencing (stage II) of the top 20% (i.e. 12) genes on 288 to 928 14 
additional cases and 288 to 1,216 additional controls, depending on intermediate results.  The 15 
procedure was identical to stage I: high-throughput resequencing of pooled amplicons obtained from 16 
DNA pools of cases or controls (32 individuals/pool; up to 29 case and 38 control pools/gene).  17 
Amplicons were appended with DNA pool-specific tags allowing simultaneous sequencing of multiple 18 
DNA pools.  Average sequence depth in stage II was 988 ± 512 (range: 411 – 13,506) in cases, and 19 
1,019 ± 415 (range: 405 – 10,414) in controls (Supplemental Fig. 1 & Supplemental Table 3). We 20 
detected 2 new common and 112 new rare variants (Supplemental Table 7).  We observed no 21 
difference in sequence depth between amplicon x DNA pool combinations in which rare DSV were 22 
detected and those in which no such DSV were found (Supplemental Fig. 3).  23 
We tested for differences in cumulative frequencies of rare variants in cases and controls using the 24 
same permutation test as above except that we only tested the significance of the enrichment with 25 
same polarity as in stage I, i.e. enrichment either for rare risk variants in cases (FGFR1OP, GSDMB, 26 
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IKZF3, IL1RL1, NOD2, SLC9A4, TNFSF8) or rare protective variants in controls (CCL8, CDKAL1, ENOX1, 1 
IL23R, SLC22A5).    At the outcome of stage II (Table 2), one gene yielded a suggestive association 2 
(FGFR1OP; nominal p = 0.040; Bonferonni-corrected p = 0.386), and one gene yielded a significant 3 
association (IL23R; nominal p = 2.67 x 10-3; Bonferonni-corrected p = 0.0314).  4 
Closer examination of FGFR1OP revealed that three NS variants (p.T184I, p.K251N, p.S281P) located 5 
within 2,436 bp from each other were segregating identically across DNA pools.  This strongly 6 
suggested that they were in complete LD.  When considering them as a single event, nominal p-7 
values dropped to 0.124 in stage I and 0.081 in stage II.  Hence, FGFR1OP was not considered for 8 
further analysis.   9 
The IL23R signal was entirely due to three variants (p.R86Q, p.G149R and p.V362I) with cumulative 10 
frequency of 0.0052 in cases versus 0.0370 in controls in stage I and 0.0088 in cases versus 0.0193 in 11 
controls in stage II (Table 3 and Supplemental Table 8). The observation of an enrichment in controls 12 
of these presumably protective IL23R variants was consistent with the protective effect of p.R381Q 13 
that lead to the discovery of IL23R by GWAS20.  p.R381Q was enriched in our controls as expected (p 14 
= 8.49 x 10-9).  15 
Being low frequency rather than very rare DSV4 allowed targeted genotyping in independent 16 
samples.  We developed TaqMan assays for p.R86Q, p.G149R and p.V362I in addition to p.R381Q.  17 
We first genotyped the sequenced individuals, which confirmed the enrichment of the p.R86Q, 18 
p.G149R and p.V362I variants in controls (Table 3 and Supplemental Fig. 2).  We then genotyped an 19 
additional 1,565 CD patients, 2,000 controls and 3,101 familial samples (740 affected, 2,361 non-20 
affected) (stage III).  All analyzed individuals were of European decent and most of them previously 21 
used in GWAS replications.  p.G149R (p = 0.022) and p.V362I (p = 1.51 x 10-3) were significantly 22 
enriched in controls in the replication cohort while a similar trend, albeit not strictly significant, was 23 
observed for the rarer p.R86Q variant (p = 0.057) (Table 4).  24 
p.R381Q confers protection against ulcerative colitis (UC)20 (as well as ankylosing spondylitis21).  We 25 
thus genotyped a cohort of 1,251 European decent UC patients for the same four IL23R DSV.  Both 26 
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p.R381Q (p = 9.03 x 10-9) and p.V362I (p = 8.31 x 10-3) were significantly depleted in UC patients, 1 
while the expected trend was observed for p.G149R (p = 0.087), but not for p.R86Q (p = 0.613) (Table 2 
5). 3 
We herein describe the systematic search for rare coding variants influencing inherited 4 
predisposition to CD in 63 positional candidates identified by GWAS.  We report three novel low 5 
frequency IL23R variants protecting against CD:  p.R86Q, p.G149R and p.V362I.  The three same 6 
variants were found to be protective in an independent study, hence strengthening our claims (M. 7 
Rivas & M. Daly, personal communication). We present preliminary evidence that p.G149R and 8 
p.V362I act protectively against UC as well, as would be expected from the equivalent effect of 9 
p.R381Q. 10 
As for the previously described p.R381Q, the novel p.R86Q, p.G149R and p.V362I variants are 11 
assumed to be hypomorphs dampening IL23R signaling.  p.G149R and p.R381Q affect extremely 12 
conserved residues in the extracellular and intracellular domain of the receptor, respectively, and are 13 
predicted by SIFT19 to be damaging.  p.R86Q and p.V362I, on the contrary, affect poorly conserved 14 
residues and are predicted to be “tolerated” by SIFT19 (using sequence information only) and 15 
“benign” by PolyPhen22 (using sequence and structural information).   Moreover, the reference IL23R 16 
sequences of some mammals carry the Q and I residues associated with IBD in human.  While we 17 
cannot exclude that p.R86Q and p.V362I are enriched in cases because of their association with 18 
causative variants lying outside the ORF, we consider it more parsimonious that they affect IL23R 19 
signaling directly.  Of note, relative protection conferred by the “damaging” p.G149R and p.R381Q 20 
(2.98 and 2.75) tended to be higher than that conferred by the “tolerated” p.R86Q and p.V362I (2.50 21 
and 1.76), and the same  tendency was observed for UC.  22 
Relative protection against CD conferred by the newly detected low frequency variants was 2.4 on 23 
average.  Although possible overestimated (winner’s curse), this value appears considerably larger 24 
than the 1.2 relative risk conferred by the bulk of common effects detected in GWAS, and supports 25 
an increase in effect size with decreasing frequency6.  However, the newly detected variants jointly 26 
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explain only 0.18% of the variance of the underlying liability, to be compared with 0.85% for the 1 
more common p.R381Q and rs7517847 variants19 (Supplemental note 3).  Haplotype analysis 2 
indicates that protection conferred by p.R86Q, p.G149R and p.V362I is largely independent of the 3 
more common p.R381Q and rs7517847, i.e. we provide no evidence for “synthetic association” 23 at 4 
the IL23R locus (Supplemental note 3).     5 
Although not significant when accounting for multiple testing, we obtained evidence suggesting an 6 
enrichment of rare NS NOD2 risk variants in cases in stage I, supporting previous reports14,15.  This 7 
enrichment was not confirmed in stage II despite the sequencing of 928 cases and 992 controls.  This 8 
discrepancy may be related to the selection of stage I samples carrying neither of the previously 9 
described p.R702W, p.G908R or p.A1007fs NOD2 susceptibility variants, which were consequently 10 
enriched in stage II samples.  Considering stage I and II samples jointly, however, indicates that the 11 
excess NOD2 mutation load in CD cases is likely to be lower than previously assumed14,15, more in line 12 
with recent estimates from a similarly conducted North-American scan for rare variants (M. Rivas & 13 
M. Daly, personal communication).  14 
Our findings are highly reminiscent of those of Nejentsev et al.12, who resequenced the ORF and 15 
regulatory regions of ten candidates for type I diabetes in 480 cases and 480 controls and reported 16 
four low frequency protective variants in IFIH1.  These modest success rates contrast with Johansen 17 
et al.13 who reported an enrichment of rare variants associated with hypertriglyceridemia (HTG; 18 
defined as fasting plasma triglyceride concentrations above the 95th percentile) in all four 19 
resequenced (438 cases and 327 controls) candidate genes from GWAS (APOA5, GCKR, LPL, APOB).   20 
We performed simulations indicating that this discrepancy is more likely to result from a difference in 21 
genomic architecture of the studied traits rather than from methodological ideosyncrasies (high-22 
throughput sequencing of DNA pools in two stages versus Sanger sequencing of individual samples in 23 
one stage) (Supplemental note 4). 24 
This study confirms the enrichment of low frequency variants (either in cases or controls) in at least 25 
some genes underlying inherited predisposition to complex diseases.  Our results support an increase 26 
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in effect size with decreasing variant frequency. However, because of their frequency rare variants 1 
explain less of the heritability than their common counterparts. Achieving adequate power to reliably 2 
detect low frequency variants will require resequencing of cohorts larger than in this study.  This will 3 
become increasingly feasible as sequencing technology continues to improve. The demonstration of 4 
an enrichment of rare or low frequency variants in candidate genes could then become an effective 5 
way to demonstrate the causality of candidate genes from GWAS.  6 
 7 
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Figure 1: Frequency distribution of MAF for (i) synonymous (blue), (ii) all non-synonymous (red), (iii) 24 
damaging (SIFT19) non-synonymous DSV (orange). 25 
 26 
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Methods 1 
High-throughput pyrosequencing on Roche FLX. Genomic DNA concentrations were determined by 2 
Quant-iT PicoGreen dsDNA Reagent and Kits (Invitrogen) for the constitution of equimolar pools of 3 
32 cases or controls (except one pool of 48 in stage I). Primer pairs for PCR were selected using 4 
Primer 324, avoiding known SNP positions. Amplicon-specific PCR reactions were set up in 30 μl 5 
volumes containg 6 μl of 5x Phusion HF buffer, 200 μM of each dNTP, 0.5 μM of each primer, and 0.6 6 
U of Phusion High-Fidelity DNA Polymerase (Finnzymes Oy).  Cycling conditions were 98 °C for 2 min, 7 
32 cycles at 98 °C for 10 sec, 60 °C for 30 sec and 72 °C for 15 sec, followed by 72 °C for 10 min on a 8 
GeneAmp PCR System 2700 thermal cycler (Applied Biosystems). PCR products were purified using 9 
MultiScreen PCRµ96 Filter Plates (Millipore), and quantified with the Quant-iT PicoGreen dsDNA 10 
reagent and kit.  Up to 300  amplicons were combined in equimolar ratios. Pooled amplicons were 11 
concentrated using the Montage PCR Filter Units (Millipore) and purified using the AMPure kit 12 
(Agencourt Biosciences). Final concentration and length distribution were measured using the 13 
Experion DNA 1K Analysis kit (Bio-Rad) on Experion Automated Electrophoresis Station (Bio-Rad).  14 
High-throughput pyrosequencing was carried out using both primer A and B on a Roche 454 Genome 15 
Sequencer FLX instrument following the recommendations of the manufacturer18. 16 
DSV detection.  Image and data were processed with the Genome Sequencer FLX System Software 17 
Package (Roche).  DSV were extracted from sff files using the AVA software. AVA reports DSV if 18 
observed at least four times and representing ≥ 0.5% of the reads.  From the AVA-generated list, we 19 
eliminated DSV (i) unless observed on both W&C strand, (ii) with flanking DSV  within 2-bp on both 20 
sides, (iii) in or within 6-bp from a homopolymer (≥5x) track, (iv) corresponding to C/A or G/T 21 
substitutions with frequency < 0.025 (cfr. Supplemental note 1). 22 
Testing for a differential load of rare variants in cases and controls from resequencing data.  Excess 23 
load of rare variants in cases (risk variants) or controls (protective variants) was tested on a gene-by-24 
gene basis, and - within gene – by DSV variant type (S, NS+β, damaging).  Rare variants were defined 25 
as DSV with MAF < 0.05.  The results were essentially unaffected by the threshold frequency used to 26 
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define rare variants (0.02 - 0.05) (data not shown).  DSV read counts (number of reads with the 1 
DSV/total number of reads for that amplicon) were converted to the closest chromosome counts (>0) 2 
(number of chromosomes with the DSV/total number of chromosomes in the pool = 64) and these 3 
were summed over DNA pools, separately for cases and controls. The p-value of the difference in 4 
DSV chromosome counts between cases and controls was then computed using two one-tailed 5 
Fisher’s exact tests, one testing an excess in cases (risk), the other in controls (protective).  For a 6 
given gene, we then multiplied hypothesis-specific (risk and protective) p-values across rare variants, 7 
to generate two gene-specific summary p-values.  The statistical significance of these summary 8 
statistics was estimated by permutation testing.  For each rare DSV, case vs control status of mutant 9 
chromosomes were assigned randomly yet accounting for the possibility that the number of 10 
successfully sequenced chromosomes (i.e. DNA pools) might differ between cases and controls.  The 11 
same two gene-specific summary p-values were generated for 1,000,000 permutations, and the 12 
significance of the p-values obtained with the real data estimated as the proportion of permutations 13 
with lower, hypothesis-specific, summary p-value.  14 
Case-control and familial association test based on individual genotypes. SNPs were tested on 15 
individual DNA using custom TaqMan assays (Applied Biosystems).  The statistical significance of the 16 
difference in DSV frequency between cases and controls was estimated using one-side Fisher’s exact 17 
test.  The familial cohort was used to evaluate the significance of the distorted segregation of DSV 18 
p.R381Q and p.V362I (TDT) from heterozygous parents to affected offspring using a custom-made 19 
script. As no heterozygous parents were available in the familial cohort for DSV p.R86Q and p.G149R, 20 
one affected individual per family was added to the case cohort in the case-control analysis for the 21 
analysis of these variants.  Combining test statistics were done across resequencing, case-control and 22 
TDT experiments using a permutation test akin to the one described above. 23 
 24 
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